Fig. 6
From: Epithelial tumor suppressor ELF3 is a lineage-specific amplified oncogene in lung adenocarcinoma
Prognostic relevance of ELF3 expression in non-small cell lung cancer. Kaplan–Meier survival curves comparing overall survival of lung cancer patients with high or low ELF3 expression (top and bottom tertiles, log-rank p values). All Stages: NSCLC n = 1926, p = 4.65E-04, Hazard Ratio (HR) (95% confidence interval) = 1.32 (1.13–1.55); LUAD n = 720, p = 5.09E-07, HR = 2.08 (1.57–2.76); LUSC n = 524, p = 0.229, HR = 1.20 (0.89–1.60). Stage I: NSCLC n = 577, p = 2.30E-05, HR = 2.11 (1.51–2.95); LUAD n = 370, p = 1.00E-06, HR = 3.66 (2.27–5.88); LUSC n = 172, p = 0.357, HR = 1.27 (0.76–2.14). NSCLC = non-small cell lung cancer; LUAD = lung adenocarcinoma; LUSC = lung squamous cell carcinoma.
